Related Experiment Video
Updated: Jan 14, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Major Changes in Systemic Therapy for Advanced Melanoma
1Presented by John A. Thompson, MD, Division of Medical Oncology, University of Washington School of Medicine/Seattle Cancer Care Alliance, Seattle, Washington.
Abstract:
Over the past 5 years, a host of new agents have radically changed the therapeutic landscape in advanced melanoma; gone are the days when the only active agents were interferon and dacarbazine. Nearly 25 years ago, few patients with stage IV melanoma reached 2-year survival; today, these survival curves have risen substantially. At the NCCN 21st Annual Conference, John A. Thompson, MD, discussed updates with longer duration of patient follow-up for immune checkpoint therapies. He also reviewed some of the newer approvals in advanced melanoma, including the combination of ipilimumab and nivolumab, high-dose ipilimumab, the oncolytic virus therapy talimogene laherparepvec, and the molecularly targeted combination of the BRAF and MEK inhibitors vemurafenib and cobimetinib.
Insights
Newer therapies have significantly improved survival for advanced melanoma patients. Immune checkpoint inhibitors and targeted therapies offer better outcomes than older treatments like interferon and dacarbazine.
Area of Science:
- Oncology
- Immunotherapy
- Medical Treatments
Background:
- Advanced melanoma treatment has evolved significantly over the last five years.
- Historically, survival rates for stage IV melanoma were low, with limited effective treatments such as interferon and dacarbazine.
- Recent advancements have dramatically improved patient survival and therapeutic options.
Purpose of the Study:
- To review updates and longer-term patient follow-up data for immune checkpoint therapies in advanced melanoma.
- To discuss newly approved treatments for advanced melanoma.
- To highlight the impact of novel therapeutic agents on patient survival.
Main Methods:
- Review of clinical data and conference presentations on advanced melanoma treatments.
- Discussion of immune checkpoint inhibitors, including ipilimumab and nivolumab.
- Overview of oncolytic virus therapy (talimogene laherparepvec) and targeted therapy combinations (BRAF and MEK inhibitors).
Main Results:
- Immune checkpoint therapies demonstrate improved survival outcomes with longer follow-up.
- Combination therapies, such as ipilimumab and nivolumab, show substantial survival benefits.
- Newer agents like talimogene laherparepvec and BRAF/MEK inhibitor combinations offer additional treatment avenues.
Conclusions:
- Modern therapeutic strategies, particularly immune checkpoint inhibitors and targeted therapies, have transformed advanced melanoma treatment.
- These advancements have led to significantly increased 2-year survival rates compared to historical data.
- Continued research and longer-term follow-up are crucial for understanding the full impact of these novel agents.
Related Concept Videos
02:56Treatment Resistant Cancers
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...